PHI with Trilogy of Fallot
How does this condition affect your private health insurance?
Trilogy of Fallot is a rare congenital heart defect characterized by three main anomalies: pulmonary stenosis (narrowing of the pulmonary valve or artery), an atrial septal defect (ASD) allowing blood to flow between the atria, and right ventricular hypertrophy (thickening of the right heart muscle). Unlike Tetralogy of Fallot, it lacks a ventricular septal defect and overriding aorta. Symptoms, including cyanosis, shortness of breath, and fatigue, typically appear in infancy or early childhood. Diagnosis involves echocardiography. Surgical correction is the primary treatment to improve blood flow to the lungs and close the ASD, significantly improving prognosis and quality of life. Lifelong follow-up is essential.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Congenital, symptoms often manifest within the first year of life and persist until diagnosis and treatment.
Duration of Illness (Lifetime)
Lifelong condition requiring ongoing medical follow-up, even after successful surgical repair.
Cost of Treatment (Initial)
High (e.g., USD 50,000 - 200,000+), involving extensive diagnostics, hospitalization, and open-heart surgery.
Cost of Treatment (Lifetime)
High (e.g., USD 100,000 - 500,000+), including follow-up cardiology visits, medications, potential re-interventions, and management of complications.
Mortality Rate
Significant (e.g., 20-40% or higher) without surgical intervention in early life; significantly reduced (e.g., <5%) with successful modern surgical repair, but risks remain.
Risk of Secondary Damages
High (e.g., 60-80%) without timely intervention, including chronic cyanosis, heart failure, arrhythmias, pulmonary hypertension, endocarditis, and developmental delays.
Probability of Full Recovery
Moderate (e.g., 50-70%) for a good functional outcome post-surgery, allowing a relatively normal life, but complete anatomical and physiological normalization without any residual issues is rare; lifelong monitoring is typically required.
Underlying Disease Risk
Low to moderate (e.g., 10-20%), as it can occasionally be associated with genetic syndromes (e.g., Down syndrome, DiGeorge syndrome) or other congenital anomalies, though less frequently than some other complex heart defects.